What is Infliximab?

Category: Prescription Drugs

Most popular types: Remicade Revellex Infimab

false

Infliximab is a monoclonal antibody used in the treatment of a number of autoimmune conditions, including: Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Crohn's disease 163 75
Rheumatoid arthritis 103 54
Psoriatic arthritis 40 23
Ulcerative colitis 40 23
Ankylosing spondylitis 31 15

Show all 32 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 29
Moderate 40
Mild 55
None 68

Commonly reported side effects and conditions associated with Infliximab

Side effect Patients Percentage
Fatigue 20
Nausea 11
Headaches 10
Joint pain 7
Muscle and joint pain 6
Anaphylaxis 4

Show all 82 reported side effects

Dosages

Based on patients currently taking Infliximab

Dosage Patients Percentage
100 mg every 6 weeks 3
400 mg every 8 weeks 3
1 mg every 8 weeks 1
56 mg every 6 weeks 1
100 mg every 8 weeks 1
180 min every 6 weeks 1
300 mg every 8 weeks 1
300 mg every 6 weeks 1
500 mL every 6 weeks 1
700 mg every 6 weeks 1

See all 12 dosages

Why patients stopped taking Infliximab

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 75
Side effects too severe 61
Other 43
Doctor's advice 40
Expense 17
Change in health plan coverage 9
Course of treatment ended 5
Personal research 1
See all 183 patients who've stopped taking Infliximab

Duration

Currently taking Infliximab

Duration Patients Percentage
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 3
2 - 5 years 4
5 - 10 years 6
10 years or more 1

Stopped taking Infliximab

Duration Patients Percentage
Less than 1 month 33
1 - 6 months 29
6 months - 1 year 36
1 - 2 years 30
2 - 5 years 38
5 - 10 years 14
10 years or more 5
Adherence
Adherence Evaluations Percentage
Always 167
Usually 10
Sometimes 6
Never taken as prescribed 9
Burden
Burden Evaluations Percentage
Very hard to take 13
Somewhat hard to take 70
A little hard to take 56
Not at all hard to take 53
Cost per month
Cost per month Evaluations Percentage
$200+ 28
$100-199 10
$50-99 7
$25-49 5
< $25 47
Not specified 95

What people switch to and from

Patients started taking Infliximab after stopping:

Treatment Patients Percentage
Adalimumab (Humira) 19
Mesalamine (Pentasa) 10
Etanercept (Enbrel SureClick) 9
Prednisone (Deltasone) 7
Methotrexate (Trexall) 5

Show all 26 treatments patients report switching from

Patients stopped taking Infliximab and switched to:

Treatment Patients Percentage
Adalimumab (Humira) 23
Abatacept (Orencia) 9
Golimumab (Simponi SmartJect) 4
Tocilizumab (Actemra) 4
Certolizumab (Cimzia) 3

Show all 21 treatments patients report switching to

Last updated:

9 patient evaluations for Infliximab

Mar 22, 2017 (Started Mar 03, 2017)

  • Effectiveness
    Slight (for psoriasis worsened)
  • Effectiveness
    Slight (for psoriatic arthritis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 6 mg Every 8 Weeks

  • 0 helpful marks

Jul 21, 2016 (Started Dec 12, 2015)

  • Effectiveness
    Moderate (for Crohn's disease)
  • Effectiveness
    Major (for rheumatoid arthritis)
  • Side effects
    Moderate (dry throat, dry skin, rash or skin problems)
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 600 mg Every 8 Weeks
Advice & Tips: It takes commitment and time to work. My infusions are done at the GI clinic while some are outpatient at hospital. They take 3-4 hours and usually am extremely tired and groggy for couple of days.
Cost: $200+ monthly

  • 1 helpful mark

Jun 25, 2013 (Started Jul 01, 2005)

  • Effectiveness
    Major (for Crohn's disease)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 375 mg Every 6 Weeks

  • 0 helpful marks
Last updated:
Showing 3 of 9 patient evaluations for Infliximab